PPAR activation as a regulator of lipid metabolism, nitric oxide production and lipid peroxidation in the placenta from type 2 diabetic patients

Molecular and Cellular Endocrinology

Volumn 377, Issue 1-2, 2013, Pages 7-15

  Capobianco, Evangelina ^a   Martínez, Nora ^a   Fornes, Daiana ^a   Higa, Romina ^a   Di Marco, Ingrid ^b   Basualdo, María Natalia ^b   Faingold, María Cristina ^c   Jawerbaum, Alicia ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

^b Hospital Materno Infantil Ramon Sarda   (Argentina)

^c Unidad Asistencial Dr César Milstein   (Argentina)

Author keywords

Diabetes in pregnancy; Lipid metabolism; Nitric oxide; Placenta; PPARs

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; LIPID; LIPID PEROXIDE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIPID METABOLISM; LIPID PEROXIDATION; MATERNAL DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLACENTA; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; TISSUE LEVEL;

15DEOXYΔ(12,14)PGJ(2); 15DPGJ(2); CARBAPROSTACYCLIN; CLOF; CLOFIBRATE; CPGI(2); DIABETES IN PREGNANCY; GDM; GESTATIONAL DIABETES MELLITUS; GW; GW501516; LEUKOTRIENE B(4); LIPID METABOLISM; LTB(4); NITRIC OXIDE; NO; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PG; PGI(2); PLACENTA; PPAR; PPARS; PROSTACYCLIN OR PROSTAGLANDIN I(2); PROSTAGLANDIN; ROSI; ROSIGLITAZONE; TBARS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

ADULT; BLOTTING, WESTERN; DENSITOMETRY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIGANDS; LIPID METABOLISM; LIPID PEROXIDATION; NITRIC OXIDE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLACENTA; PREGNANCY; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84880338336     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.06.027     Document Type: Article

References (46)

1. Aye I.L., Waddell B.J., Mark P.J., Keelan J.A. Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity. Biochim. Biophys. Acta 2010, 1801:1013-1024.
2. Balsells M., Garcia-Patterson A., Gich I., Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 2009, 94:4284-4291.
3. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., Boland R., Evans R.M. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. USA 2002, 99:303-308.
4. Barak Y., Sadovsky Y., Shalom-Barak T. PPAR signaling in placental development and function. PPAR Res. 2008, 2008:142082.
5. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
6. Bildirici I., Roh C.R., Schaiff W.T., Lewkowski B.M., Nelson D.M., Sadovsky Y. The lipid droplet-associated protein adipophilin is expressed in human trophoblasts and is regulated by peroxisomal proliferator-activated receptor-gamma/retinoid X receptor. J. Clin. Endocrinol. Metab. 2003, 88:6056-6062.
7. Capobianco E., Jawerbaum A., Romanini M.C., White V., Pustovrh C., Higa R., Martinez N., Mugnaini M.T., Sonez C., Gonzalez E. 15-Deoxy-Delta12,14-prostaglandin J2 and peroxisome proliferator-activated receptor gamma (PPARgamma) levels in term placental tissues from control and diabetic rats: modulatory effects of a PPARgamma agonist on nitridergic and lipid placental metabolism. Reprod. Fertil. Dev. 2005, 17:423-433.
8. Capobianco E., White V., Higa R., Martinez N., Jawerbaum A. Effects of natural ligands of PPARgamma on lipid metabolism in placental tissues from healthy and diabetic rats. Mol. Hum. Reprod. 2008, 14:491-499.
9. Capobianco E., White V., Sosa M., Marco I.D., Basualdo M.N., Faingold M.C., Jawerbaum A. Regulation of matrix metalloproteinases 2 and 9 activities by peroxynitrites in term placentas from type 2 diabetic patients. Reprod. Sci. 2012, 19:814-822.
10. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 2001, 7:53-58.
11. Desoye G., Gauster M., Wadsack C. Placental transport in pregnancy pathologies. Am. J. Clin. Nutr. 2011, 94:1896S-1902S.
12. Desvergne B., Michalik L., Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol. Endocrinol. 2004, 18:1321-1332.
13. Desvergne B., Michalik L., Wahli W. Transcriptional regulation of metabolism. Physiol. Rev. 2006, 86:465-514.
14. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA 1997, 94:4312-4317.
15. Fournier T., Guibourdenche J., Handschuh K., Tsatsaris V., Rauwel B., Davrinche C., Evain-Brion D. PPARgamma and human trophoblast differentiation. J. Reprod. Immunol. 2011, 90:41-49.
16. Gauster M., Desoye G., Totsch M., Hiden U. The placenta and gestational diabetes mellitus. Curr. Diab. Rep. 2012, 12:16-23.
17. Herrera E., Ortega-Senovilla H. Disturbances in lipid metabolism in diabetic pregnancy - are these the cause of the problem?. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24:515-525.
18. Herrera E., Amusquivar E., Lopez-Soldado I., Ortega H. Maternal lipid metabolism and placental lipid transfer. Horm. Res. 2006, 65(Suppl. 3):59-64.
19. Higa R., Gonzalez E., Pustovrh M.C., White V., Capobianco E., Martinez N., Jawerbaum A. PPARdelta and its activator PGI2 are reduced in diabetic embryopathy: involvement of PPARdelta activation in lipid metabolic and signalling pathways in rat embryo early organogenesis. Mol. Hum. Reprod. 2007, 13:103-110.
20. Holdsworth-Carson S.J., Lim R., Mitton A., Whitehead C., Rice G.E., Permezel M., Lappas M. Peroxisome proliferator-activated receptors are altered in pathologies of the human placenta: gestational diabetes mellitus, intrauterine growth restriction and preeclampsia. Placenta 2010, 31:222-229.
21. Hostetler H.A., Petrescu A.D., Kier A.B., Schroeder F. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands. J. Biol. Chem. 2005, 280:18667-18682.
22. Jawerbaum A., Capobianco E. Review: effects of PPAR activation in the placenta and the fetus: implications in maternal diabetes. Placenta 2011, 32(Suppl. 2):S212-S217.
23. Jawerbaum A., Capobianco E., Pustovrh C., White V., Baier M., Salzberg S., Pesaresi M., Gonzalez E. Influence of peroxisome proliferator-activated receptor gamma activation by its endogenous ligand 15-deoxy Delta12,14 prostaglandin J2 on nitric oxide production in term placental tissues from diabetic women. Mol. Hum. Reprod. 2004, 10:671-676.
24. Katsiki N., Nikolic D., Montalto G., Banach M., Mikhailidis D.P., Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des. 2013.
25. Kurtz M., Capobianco E., Martinez N., Fernandez J., Higa R., White V., Jawerbaum A. Carbaprostacyclin, a PPARdelta agonist, ameliorates excess lipid accumulation in diabetic rat placentas. Life Sci. 2010, 86:781-790.
26. Lappas M., Permezel M., Rice G.E. 15-Deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta 2006, 27:1060-1072.
27. Lappas M., Hiden U., Desoye G., Froehlich J., Mouzon S.H., Jawerbaum A. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. Antioxid. Redox Signal. 2011, 15:3061-3100.
28. Leach L., Taylor A., Sciota F. Vascular dysfunction in the diabetic placenta: causes and consequences. J. Anat. 2009, 215:69-76.
29. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12953-12956.
30. Leone T.C., Weinheimer C.J., Kelly D.P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA 1999, 96:7473-7478.
31. Martinez N., Kurtz M., Capobianco E., Higa R., White V., Jawerbaum A. PPARalpha agonists regulate lipid metabolism and nitric oxide production and prevent placental overgrowth in term placentas from diabetic rats. J. Mol. Endocrinol. 2011, 47:1-12.
32. Martinez N., White V., Kurtz M., Higa R., Capobianco E., Jawerbaum A. Activation of the nuclear receptor PPARalpha regulates lipid metabolism in foetal liver from diabetic rats: implications in diabetes-induced foetal overgrowth. Diabetes Metab. Res. Rev. 2011, 27:35-46.
33. Melamed N., Hod M. Perinatal mortality in pregestational diabetes. Int. J. Gynaecol. Obstet. 2009, 104(Suppl. 1):S20-S24.
34. Michael Weindling A. Offspring of diabetic pregnancy: short-term outcomes. Semin. Fetal Neonatal Med. 2009, 14:111-118.
35. Negre-Salvayre A., Auge N., Ayala V., Basaga H., Boada J., Brenke R., Chapple S., Cohen G., Feher J., Grune T., Lengyel G., Mann G.E., Pamplona R., Poli G., Portero-Otin M., Riahi Y., Salvayre R., Sasson S., Serrano J., Shamni O., Siems W., Siow R.C., Wiswedel I., Zarkovic K., Zarkovic N. Pathological aspects of lipid peroxidation. Free Radic. Res. 2010, 44:1125-1171.
36. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
37. Panadero M.I., Gonzalez M.C., Herrera E., Bocos C. Factors modulating fibrates response: therapeutic implications and alternative strategies. Endocr. Metab. Immune Disord. Drug Targets 2009, 9:219-236.
38. Pustovrh M.C., Capobianco E., Martinez N., Higa R., White V., Jawerbaum A. MMP/TIMP balance is modulated in vitro by 15dPGJ(2) in fetuses and placentas from diabetic rats. Eur. J. Clin. Invest. 2009, 39:1082-1090.
39. San Martin R., Sobrevia L. Gestational diabetes and the adenosine/l-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta 2006, 27:1-10.
40. Schaiff W.T., Bildirici I., Cheong M., Chern P.L., Nelson D.M., Sadovsky Y. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor signaling regulate fatty acid uptake by primary human placental trophoblasts. J. Clin. Endocrinol. Metab. 2005, 90:4267-4275.
41. Scifres C.M., Chen B., Nelson D.M., Sadovsky Y. Fatty acid binding protein 4 regulates intracellular lipid accumulation in human trophoblasts. J. Clin. Endocrinol. Metab. 2011, 96:E1083-E1091.
42. Vambergue A., Fajardy I. Consequences of gestational and pregestational diabetes on placental function and birth weight. World J. Diabetes 2011, 2:196-203.
43. Wang H., Xie H., Sun X., Tranguch S., Zhang H., Jia X., Wang D., Das S.K., Desvergne B., Wahli W., DuBois R.N., Dey S.K. Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success. J. Biol. Chem. 2007, 282:37770-37782.
44. White V., Gonzalez E., Capobianco E., Pustovrh C., Martinez N., Higa R., Baier M., Jawerbaum A. Leptin modulates nitric oxide production and lipid metabolism in human placenta. Reprod. Fertil. Dev. 2006, 18:425-432.
45. Wieser F., Waite L., Depoix C., Taylor R.N. PPAR action in human placental development and pregnancy and its complications. PPAR Res. 2008, 2008:527048.
46. Yessoufou A., Hichami A., Besnard P., Moutairou K., Khan N.A. Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: modulation of T cell differentiation. Endocrinology 2006, 147:4410-4418.